Back to search results

Mankind Pharma

Explore carbon emissions data for Mankind Pharma. Mycelium helps you review reported emissions, disclosure status, Scope 1, Scope 2 and Scope 3 data, climate targets and sustainability information in one company profile.

This profile brings together available carbon emissions data for Mankind Pharma, including reported figures, modelled estimates, disclosure documents and sustainability indicators, so you can review its emissions and compare its performance against similar companies. It is one entry in the Mycelium emissions database. Read how we source and check this data.

Emissions

Carbon emissions

Total yearly emissions across all scopes

209,208tCO2e(Location Based)(Mycelium adjusted)

Reported by Mankind Pharma
35,743 tCO₂e
Estimated by Mycelium
173,465 tCO₂e

Mankind Pharma reported 17% of the adjusted total. Mycelium estimated the remaining 83% for the categories it did not disclose.

Scope 1

tCO2e

6,538

Scope 2 (Location Based)

tCO2e

29,205

Scope 3 total

tCO2e

173,465

Figures from page 37 of the source report

Scope 3 reported

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15

Something wrong? Contribute to this dataset

See the scope breakdown

Provenance

Review the sources and documents behind Mankind Pharma's emissions data. Provenance matters because it shows where the information comes from, how recent it is and how complete the disclosure appears to be.

Documents

Emissions
Factors

Modelled emission factorScope 1, 2 and upstream Scope 3 (categories 1–8)
0.173kgCO2e / $

Sustainability
Snapshot

Based on reported data, retrieved with AI

  • Mankind Pharma reported 35,743 tCO₂e in 2025.
  • Scope 2 reported under the location based methodology.

According to available emissions disclosures, Mankind Pharma reported total yearly emissions of 35,743 tCO₂e in 2025. Scope 2 emissions accounted for 82% of the reported footprint, indicating purchased energy was the most significant contributor to its carbon footprint.

The company achieved a Mycelium Score of 1.2, placing it well below average for its sector for sustainability performance, and received a transparency score of 18.4, pointing to very little public detail on their key emissions.

Scope
breakdown

Scope 1 emissions

Direct emissions from sources the company owns or controls, such as fuel use, facilities and vehicles.

REPORTED

Direct emissions

6,538

tCO2e

Scope 2 emissions

Indirect emissions from purchased energy, including electricity, heating and cooling.

REPORTED

Location based

29,205

tCO2e

Market based

–

tCO2e

Scope 3 emissions

Wider value chain emissions across the 15 GHG Protocol categories, from purchased goods and business travel to investments, where reported.

ESTIMATED

Cat 1

Purchased goods & services

94,470

tCO2e
ESTIMATED

Cat 2

Capital goods

6,759

tCO2e
ESTIMATED

Cat 3

Fuel & energy related activities

5,270

tCO2e
ESTIMATED

Cat 4

Upstream transportation & distribution

6,126

tCO2e
ESTIMATED

Cat 5

Waste generated in operations

4,522

tCO2e
ESTIMATED

Cat 6

Business travel

19,963

tCO2e
ESTIMATED

Cat 7

Employee commuting

15,589

tCO2e
ESTIMATED

Cat 8

Upstream leased assets

381

tCO2e
ESTIMATED

Cat 9

Downstream transportation & distribution

985

tCO2e
ESTIMATED

Cat 10

Processing of sold products

1,322

tCO2e
ESTIMATED

Cat 11

Use of sold products

11,684

tCO2e
ESTIMATED

Cat 12

End-of-life treatment of sold products

1,677

tCO2e
ESTIMATED

Cat 13

Downstream leased assets

567

tCO2e
ESTIMATED

Cat 14

Franchises

3,688

tCO2e
ESTIMATED

Cat 15

Investments

462

tCO2e

15 values were derived via Mycelium's normalisation process rather than reported by the company. A cell marked “ESTIMATED” is a figure the company did not disclose, modelled by Mycelium.

Verification

Independent third parties involved in checking or preparing Mankind Pharma's emissions data.

Independent assurance

Independently assured(reasonable assurance)by TUV India Pvt. Ltd.for 2025

Contact Info

Country

India

Browse carbon emissions data by industry

How scoring works

How the Mycelium Score is calculated

The Mycelium Score is out of 10. Up to 6.5 points reflect carbon intensity vs peers in the same NACE section (emissions normalised against revenue, log-scaled between the 5th and 95th percentile of each company's latest reporting year in that section; a section needs at least 5 companies to be benchmarked). The band above 6.5 is earned through verified data quality on a claimed profile: declaring every reporting category yourself (up to 2.0), preparation by a carbon accountant (2.0) and independently audited figures (2.0). The total is multiplied by the transparency score and capped at 10. A disclosure with an implausibly large figure (Scope 1 or 2 over 300 million tonnes, a Scope 3 figure over 2 billion tonnes or a total over 2.5 billion tonnes) is not scored until it has been checked.

A higher score means lower carbon intensity than sector peers, backed by data that's third-party verified, claimed by the company, and fully disclosed. Mankind Pharma's score sits at the top of this page and in the score panel. Without a revenue figure to measure carbon intensity, or an industry classification to compare it within, a company has no score.

How the Transparency Score is calculated

The Transparency Score is the share of a company's estimated footprint that it reported itself, graded from A (very high) down to F (very low). Where a category is missing, Mycelium models what it would hold for a company of that size and industry and counts it as undisclosed, so an unreported category where the bulk of emissions sit hurts far more than a minor one. Unreported downstream categories (9 to 15) count at a quarter of their modelled size in this share; the carbon intensity behind the score still counts them in full. A Scope 3 total filed without a category breakdown earns very little credit for the part left unattributed, because it does not show which categories are inside it: a company can count business travel, leave purchased goods out entirely, and the total looks the same. Without a revenue figure the footprint cannot be modelled, so the company has no Transparency Score.

For Mankind Pharma, the single biggest gap is Purchased goods & services (Scope 3 Category 1). Mycelium estimates it accounts for around 45% of the company's estimated footprint, yet it hasn't been disclosed. Leaving a bucket this large unreported is what's holding the transparency score down.

Other material categories Mankind Pharma hasn't disclosed:

  • Business travel (Scope 3 Category 6), around 10% of the estimated footprint
  • Employee commuting (Scope 3 Category 7), around 7% of the estimated footprint
  • Use of sold products (Scope 3 Category 11), around 6% of the estimated footprint

In total, roughly 83% of Mankind Pharma's estimated emissions sit in categories it hasn't reported. Disclosing these would be the fastest way to raise the transparency score.

Cover of Mycelium's scoring methodology white paperRead the full scoring methodologyOur white paper covers exactly how the Mycelium Score and Transparency Score are calculated, including the normalisation process and what earns a 10/10.Download the white paper (PDF)

Compare Mankind Pharma with similar companies

Mankind Pharma carbon emissions FAQs

What are Mankind Pharma's carbon emissions?

In its 2025 reporting year, Mankind Pharma disclosed total emissions of 35,743 tCO2e across all scopes. Including Mycelium estimates for undisclosed categories, the adjusted total is 209,208 tCO2e. Scope 2 accounted for the largest share of the reported total, around 82%.

Does Mankind Pharma report Scope 1, Scope 2 and Scope 3 emissions?

For 2025, Mankind Pharma's available disclosure covers Scope 1 (6,538 tCO2e) and Scope 2 (29,205 tCO2e). Figures not reported by the company are shown as modelled estimates and labelled as such.

How transparent is Mankind Pharma's emissions reporting?

Mankind Pharma has a Mycelium transparency score of 18.4 out of 100. The score is the share of the company's estimated footprint that it reported itself, so an undisclosed category where most of its emissions sit weighs far more than a minor one.

Is Mankind Pharma sustainable?

Mycelium measures sustainability through carbon emissions data rather than giving a yes or no verdict. Mankind Pharma has a Mycelium Score of 1.2 out of 10, which reflects its emissions intensity against sector peers together with how transparent and well-verified its reporting is. The emissions figures and disclosure documents on this page give the fuller picture.

Is Mankind Pharma environmentally friendly?

Carbon emissions are one measurable part of environmental impact, and the part Mycelium tracks. Mankind Pharma disclosed 35,743 tCO2e for 2025, and its Mycelium Score of 1.2 out of 10 shows how that performance compares with similar companies in its sector.

Learn more about our methodology and where this data comes from.